Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis

R. K. Dixit, S. K. Satapathy, Ratnesh Kumar, R. K. Dhiman, S. K. Garg, S. Taneja, V. K. Bhargava, Y. K. Chawla

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Bacterial infections are common in patients with cirrhosis of liver and are frequently treated with ciprofloxacin. Literature on pharmacokinetics of ciprofloxacin in patients with cirrhosis of the liver is scanty. The present study compared the pharmacokinetics of ciprofloxacin in cirrhotic patients with that in healthy volunteers. Methods: In 20 patients with cirrhosis of liver (all Child-Pugh class B) and 10 healthy volunteers, plasma levels of ciprofloxacin were measured using high-performance liquid chromatography at several time points after a 500-mg oral dose. Various pharmacokinetic parameters were calculated. Results: No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] μg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination halflife (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] μg/mL.h) in healthy volunteers and cirrhotic patients, respectively. Conclusions: Pharmacokinetics of ciprofloxacin is unaltered in patients with liver cirrhosis. Ciprofloxacin can be safely administered in the usual doses in such patients.

Original languageEnglish (US)
Pages (from-to)62-63
Number of pages2
JournalIndian Journal of Gastroenterology
Volume21
Issue number2
StatePublished - Apr 25 2002

Fingerprint

Ciprofloxacin
Liver Cirrhosis
Pharmacokinetics
Healthy Volunteers
Bacterial Infections
Area Under Curve
Half-Life
High Pressure Liquid Chromatography

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Dixit, R. K., Satapathy, S. K., Kumar, R., Dhiman, R. K., Garg, S. K., Taneja, S., ... Chawla, Y. K. (2002). Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. Indian Journal of Gastroenterology, 21(2), 62-63.

Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. / Dixit, R. K.; Satapathy, S. K.; Kumar, Ratnesh; Dhiman, R. K.; Garg, S. K.; Taneja, S.; Bhargava, V. K.; Chawla, Y. K.

In: Indian Journal of Gastroenterology, Vol. 21, No. 2, 25.04.2002, p. 62-63.

Research output: Contribution to journalArticle

Dixit, RK, Satapathy, SK, Kumar, R, Dhiman, RK, Garg, SK, Taneja, S, Bhargava, VK & Chawla, YK 2002, 'Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis', Indian Journal of Gastroenterology, vol. 21, no. 2, pp. 62-63.
Dixit RK, Satapathy SK, Kumar R, Dhiman RK, Garg SK, Taneja S et al. Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. Indian Journal of Gastroenterology. 2002 Apr 25;21(2):62-63.
Dixit, R. K. ; Satapathy, S. K. ; Kumar, Ratnesh ; Dhiman, R. K. ; Garg, S. K. ; Taneja, S. ; Bhargava, V. K. ; Chawla, Y. K. / Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis. In: Indian Journal of Gastroenterology. 2002 ; Vol. 21, No. 2. pp. 62-63.
@article{a5a3ee7e76d64fa5876173fcc770139c,
title = "Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis",
abstract = "Background: Bacterial infections are common in patients with cirrhosis of liver and are frequently treated with ciprofloxacin. Literature on pharmacokinetics of ciprofloxacin in patients with cirrhosis of the liver is scanty. The present study compared the pharmacokinetics of ciprofloxacin in cirrhotic patients with that in healthy volunteers. Methods: In 20 patients with cirrhosis of liver (all Child-Pugh class B) and 10 healthy volunteers, plasma levels of ciprofloxacin were measured using high-performance liquid chromatography at several time points after a 500-mg oral dose. Various pharmacokinetic parameters were calculated. Results: No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] μg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination halflife (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] μg/mL.h) in healthy volunteers and cirrhotic patients, respectively. Conclusions: Pharmacokinetics of ciprofloxacin is unaltered in patients with liver cirrhosis. Ciprofloxacin can be safely administered in the usual doses in such patients.",
author = "Dixit, {R. K.} and Satapathy, {S. K.} and Ratnesh Kumar and Dhiman, {R. K.} and Garg, {S. K.} and S. Taneja and Bhargava, {V. K.} and Chawla, {Y. K.}",
year = "2002",
month = "4",
day = "25",
language = "English (US)",
volume = "21",
pages = "62--63",
journal = "Indian Journal of Gastroenterology",
issn = "0254-8860",
publisher = "Indian Society of Gastroenterology",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis

AU - Dixit, R. K.

AU - Satapathy, S. K.

AU - Kumar, Ratnesh

AU - Dhiman, R. K.

AU - Garg, S. K.

AU - Taneja, S.

AU - Bhargava, V. K.

AU - Chawla, Y. K.

PY - 2002/4/25

Y1 - 2002/4/25

N2 - Background: Bacterial infections are common in patients with cirrhosis of liver and are frequently treated with ciprofloxacin. Literature on pharmacokinetics of ciprofloxacin in patients with cirrhosis of the liver is scanty. The present study compared the pharmacokinetics of ciprofloxacin in cirrhotic patients with that in healthy volunteers. Methods: In 20 patients with cirrhosis of liver (all Child-Pugh class B) and 10 healthy volunteers, plasma levels of ciprofloxacin were measured using high-performance liquid chromatography at several time points after a 500-mg oral dose. Various pharmacokinetic parameters were calculated. Results: No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] μg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination halflife (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] μg/mL.h) in healthy volunteers and cirrhotic patients, respectively. Conclusions: Pharmacokinetics of ciprofloxacin is unaltered in patients with liver cirrhosis. Ciprofloxacin can be safely administered in the usual doses in such patients.

AB - Background: Bacterial infections are common in patients with cirrhosis of liver and are frequently treated with ciprofloxacin. Literature on pharmacokinetics of ciprofloxacin in patients with cirrhosis of the liver is scanty. The present study compared the pharmacokinetics of ciprofloxacin in cirrhotic patients with that in healthy volunteers. Methods: In 20 patients with cirrhosis of liver (all Child-Pugh class B) and 10 healthy volunteers, plasma levels of ciprofloxacin were measured using high-performance liquid chromatography at several time points after a 500-mg oral dose. Various pharmacokinetic parameters were calculated. Results: No significant differences were observed in maximum plasma levels reached (mean [SD] 2.6 [0.6] vs 2.6 [1.3] μg/ml), time taken for maximum plasma levels to be reached (1.3 [0.6] vs 1.5 [0.9] h), t1/2a (0.7 [0.3] vs 0.4 [0.9] h), elimination halflife (3.6 [1.2] vs 3.2 [1.8] h), and area under the curve (19.3 [3.8] vs 21.9 [4.5] μg/mL.h) in healthy volunteers and cirrhotic patients, respectively. Conclusions: Pharmacokinetics of ciprofloxacin is unaltered in patients with liver cirrhosis. Ciprofloxacin can be safely administered in the usual doses in such patients.

UR - http://www.scopus.com/inward/record.url?scp=0036229656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036229656&partnerID=8YFLogxK

M3 - Article

C2 - 11990328

AN - SCOPUS:0036229656

VL - 21

SP - 62

EP - 63

JO - Indian Journal of Gastroenterology

JF - Indian Journal of Gastroenterology

SN - 0254-8860

IS - 2

ER -